With the incorporation of novel agents in earlier lines of therapy, an increasing number of
multiple myeloma patients are refractory to traditional classes of drugs. Selinexor in …

Multiple myeloma (MM) is one the most common hematological malignancies, and despite
the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs …

Purpose Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted
accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM) …

Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …

Summary Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO 1,
also termed CRM 1). Non‐clinical studies support combining selinexor with proteasome …

Objective Multiple myeloma cells resist standard therapies due to overexpression of the
transport protein, exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein in …

e20042 Background: Selinexor is an oral, selective inhibitor of nuclear export compound
that blocks exportin 1 (XPO1), leading to retention of tumor suppressor proteins and …

Abstract Selinexor [Nexpovio®(EU); Xpovio®(USA)] is a first-in-class, selective exportin-1
inhibitor. Oral selinexor once weekly in combination with subcutaneous bortezomib once …

In recent years, the armamentarium of routinely available treatments for relapsed and/or
refractory multiple myeloma (RRMM) in Canada has dramatically expanded, but treatment …

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …